Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AGN [NYSE]
Allergan Inc.
IndexS&P 500 P/E48.74 EPS (ttm)4.29 Insider Own9.90% Shs Outstand297.90M Perf Week5.28%
Market Cap62.29B Forward P/E24.38 EPS next Y8.58 Insider Trans-0.01% Shs Float297.32M Perf Month14.05%
Income1.30B PEG2.38 EPS next Q1.83 Inst Own91.80% Short Float1.53% Perf Quarter27.99%
Sales7.01B P/S8.88 EPS this Y17.60% Inst Trans-1.78% Short Ratio1.67 Perf Half Y26.77%
Book/sh23.95 P/B8.73 EPS next Y36.09% ROA11.80% Target Price212.12 Perf Year111.95%
Cash/sh14.05 P/C14.88 EPS next 5Y20.46% ROE19.30% 52W Range94.86 - 214.20 Perf YTD88.47%
Dividend0.20 P/FCF44.53 EPS past 5Y17.90% ROI15.70% 52W High-2.39% Beta0.74
Dividend %0.10% Quick Ratio3.70 Sales past 5Y7.40% Gross Margin88.10% 52W Low120.42% ATR5.22
Employees11500 Current Ratio3.90 Sales Q/Q16.60% Oper. Margin30.80% RSI (14)71.96 Volatility2.22% 2.28%
OptionableYes Debt/Eq0.30 EPS Q/Q-6.40% Profit Margin18.50% Rel Volume1.77 Prev Close210.20
ShortableYes LT Debt/Eq0.29 EarningsOct 27 BMO Payout4.60% Avg Volume2.73M Price209.09
Recom1.80 SMA206.68% SMA5012.94% SMA20030.72% Volume4,822,937 Change-0.53%
Oct-09-14Initiated Deutsche Bank Buy $215
Oct-01-14Upgrade Stifel Hold → Buy $200
Jul-22-14Upgrade UBS Neutral → Buy $180 → $200
Apr-28-14Downgrade Stifel Buy → Hold
Apr-22-14Downgrade Argus Buy → Hold
Mar-07-14Reiterated Barclays Equal Weight $95 → $130
Feb-07-14Reiterated Argus Buy $110 → $130
Jan-08-14Reiterated Argus Buy $110 → $125
Jan-07-14Initiated RBC Capital Mkts Outperform $131
Dec-20-13Reiterated UBS Buy $100 → $116
Dec-20-13Reiterated BMO Capital Markets Outperform $112 → $117
Oct-31-13Reiterated Argus Buy $118 → $110
Jun-25-13Reiterated Canaccord Genuity Hold $111 → $98
Jun-24-13Downgrade Deutsche Bank Buy → Hold
May-02-13Reiterated RBC Capital Mkts Outperform $123 → $119
Feb-06-13Reiterated Stifel Nicolaus Buy $110 → $118
Feb-06-13Reiterated Canaccord Genuity Hold $102 → $111
Jan-22-13Reiterated Canaccord Genuity Hold $101 → $102
Sep-19-12Initiated Canaccord Genuity Hold $101
Mar-30-12Reiterated RBC Capital Mkts Outperform $93 → $106
Nov-21-14 11:15PM  Review at Barrons.com
10:54PM  [$$] Charting the Market at Barrons.com
06:27PM  ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
04:00PM  Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Zacks
03:49PM  Podcast: Do Allergan, Actavis, and Ackman Hint at a Market Top? at The Wall Street Journal
08:26AM  Allergan deal sits well on Actavis chief's 'Monopoly board' at Financial Times
04:11AM  After losing out over Allergan, Valeant announces $2 billion buyback at Fortune
Nov-20-14 06:28PM  Ackman-Valeant Alliance Proved Unwieldy at The Wall Street Journal
12:13PM  [$$] Valeant Sets $2 Billion Buyback Plan at The Wall Street Journal
Nov-19-14 06:48PM  For Allergan Suitors, Unorthodox Alliance Proved Unwieldy at The Wall Street Journal
06:14PM  Valeant Rises After Allergan Snub; Zeltiq In Buy Area at Investor's Business Daily
03:20PM  AstraZeneca Targets More than $45B in Revenues in 2023 Zacks
01:57PM  AGN SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Allergan Inc. in Connection With the Fairness of the Sale of the Company to Actavis plc Business Wire
10:26AM  US stocks retreat from records before Fed release at CNBC
09:03AM  That's Funny, you Look Just Like Allergan CEO David Pyott at The Wall Street Journal
08:37AM  Allergan's Price Tag Gets Even Richer at The Wall Street Journal
07:58AM  The Zacks Analyst Blog Highlights: Actavis, Allergan, iShares U.S. Pharmaceuticals ETF, Market Vectors Pharmaceutical ETF and SPDR S&P Pharmaceuticals ETF Zacks
07:42AM  Can the Uptrend Continue for Allergan (AGN)? Zacks
Nov-18-14 07:32PM  Cramer Remix: Warning to the skeptics at CNBC
06:26PM  Stocks rally: Dow, S&P 500 set closing highs at USA TODAY
06:19PM  [$$] Ackman Drops Push for Allergan Meeting at The Wall Street Journal
05:31PM  ALLERGAN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and E EDGAR Online
05:04PM  Vipshop, Jack in the Box Rise In After-Hours Trading at Investor's Business Daily
05:02PM  Dow, S&P 500 Add To Gains Following Encouraging International News Benzinga
04:17PM  Stocks Hit New Milestones; BitAuto Rebounds at Investor's Business Daily
03:48PM  Lifshitz & Miller Law Firm Announces Investigation of Allergan, Inc., Baker Hughes Incorporated, ChyronHego Corp., Horizon Lines, Inc., Susquehanna Bancshares, Inc., Swift Energy Company and Valley Financial Corporation PR Newswire
03:15PM  Zoetis 2015 Guidance Misses As Buyout Theories Abound at Investor's Business Daily
02:58PM  [$$] Actavis-Allergan Deal Friendly to Shareholders at Barrons.com
02:38PM  Stock Movers: Why 4 Big Drug Stocks Are Rising Today at Investor's Business Daily
01:53PM  Deals Heat Up for Lawyers Like Its 1998 Bloomberg
01:38PM  Ackman supports Allergan's $66 billion sale to Actavis Reuters
01:33PM  Stocks Hold Near Fresh Milestones; Actavis Hits New High at Investor's Business Daily
01:10PM  Ackman Pledges Support For Actavis Bid On Allergan Benzinga
12:56PM  Midday movers: Allergan, Apple, Fluor & more at CNBC
12:30PM  Actavis shares outpace buyout targets gains at MarketWatch
12:20PM  Actavis Strikes $66 Billion Deal for Botox Maker Allergan Zacks
12:08PM  Ackman withdraws special Allergan meeting CNBC
11:47AM  Jim Cramer: Which Stocks Stand Out as Winners? Here's My List at TheStreet
11:45AM  Ackman says supports Allergan's $66 billion sale to Actavis: CNBC Reuters
11:43AM  Ackman says supports Allergan's $66 billion sale to Actavis -CNBC Reuters
11:29AM  Dealpolitik: Praise for Allergan Directors, Not Pershing Square at The Wall Street Journal
11:18AM  AGN INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Allergan Inc. in Connection With the Fairness of the Sale of the Company to Actavis plc -- AGN PR Newswire
10:33AM  Stocks Most Loved By Hedge Funds at Barrons.com
10:30AM  Japan: 'Abenomics ' delivering? CNBC
10:27AM  Ackman to CNBC: Support Actavis-Allergan deal CNBC
09:22AM  Cramer's Mad Dash: Zoetis' buyback CNBC
09:03AM  [$$] Actavis Outlines Allergan Breakup Fee at The Wall Street Journal
09:01AM  Global M&A boom tops $3 trillion this year at Fortune
08:51AM  Cramer's stocks to watch: AAPL, AGN & HD CNBC
07:45AM  Pharma ETFs in Focus on Allergan Takeover Deal Zacks
07:23AM  #PreMarket Primer: Tuesday, November 18: Abe To Delay Sales Tax Increase In Japan Benzinga
06:26AM  Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics Zacks
06:08AM  Actavis' dealmaking builds drug powerhouse at Financial Times
01:09AM  PRESS DIGEST - Wall Street Journal - Nov 18 Reuters
12:40AM  Actavis Agrees to Buy Botox Maker Allergan at The Wall Street Journal
12:39AM  Jack Lew, Irish Hero at The Wall Street Journal
Nov-17-14 11:30PM  Allergan sale to Actavis thwarts takeover attempt by Valeant at Los Angeles Times +5.31%
10:26PM  Mergers and acquisitions stay on torrid pace at USA TODAY
08:39PM  Actavis to buy Botox maker Allergan for $66B at USA TODAY
08:34PM  PRESS DIGEST- British Business - Nov 18 Reuters
08:00PM  [$$] Actavis to Buy Allergan for $66 Billion at The Wall Street Journal
06:45PM  Here Are Some Big Caps Poised To Make Gains at Investor's Business Daily
06:27PM  Five Ethical Drugmakers Keep Leadership Positions at Investor's Business Daily
06:25PM  Winners and Losers From the $100 Billion M&A Day at The Wall Street Journal
06:25PM  Cramer's terrific comeback play: LULU CNBC
06:11PM  Benzinga's M&A Chatter for Monday November 17, 2014 Benzinga
06:07PM  Cramer: The lucrative journey of Allergan at CNBC
05:53PM  Allergan stock hits record after $66-billion Actavis deal at Los Angeles Times
05:31PM  Actavis Will Acquire Botox Firm Allergan For Over $66 Billion Investor's Business Daily
05:16PM  Allergan Sides With More Aggressive Dealmaker By Picking Actavis Over Valeant at Forbes
04:52PM  Actavis to spend $66 billion on Allergan AP
04:43PM  Today's quick look at the Market... Yahoo Finance Blogs
04:38PM  Allergan CEO hands Botox maker to lawyer instead of consultant at Fortune
04:29PM  Allergan agrees to $66 billion Actavis offer; Valeant walks Reuters
04:29PM  Wall Street remaining directionless for a 6th consecutive trading day Yahoo Finance Blogs
04:27PM  Allergan agrees to $66 bln Actavis offer; Valeant walks Reuters
04:16PM  Stocks End Mixed As Allergan Jumps On Actavis Deal at Investor's Business Daily
04:05PM  Allergan sees off Valeant by sealing $66bn deal with Actavis at Financial Times
03:18PM  Ackman win-win CNBC
02:26PM  Ackman Reaps $2.5 Billion From Allergan Even in Loss to Actavis at Bloomberg
01:39PM  Actavis-Allergan deal at Financial Times
01:38PM  [$$] Actavis-Allergan Deal Paves Way for Tax Savings at The Wall Street Journal
01:25PM  Losing Allergan deals blow to Valeant reputation Reuters
01:24PM  And The Winners Are Actavis, Allergan And Ackman at Forbes
01:23PM  U.S. Industrial Output Falls in October at Bloomberg
01:21PM  Actavis/Allergan: spoiler alert at Financial Times
01:05PM  Allergan deal a win for more than Ackman at CNBC
01:05PM  Allergan-Actavis deal follows battle for soul of pharma at Financial Times
01:03PM  Midday movers: Allergan, CarMax, CBS & more at CNBC
12:53PM  Bill Ackman's $2.2 Billion Day at The Wall Street Journal
12:51PM  Allergan Deal Leaves a Smile on Everyone's Face at Bloomberg
12:35PM  Zoetis attractive & durable: Pro CNBC
12:33PM  Hedge fund winners in Allergan deal CNBC
12:32PM  [video] Ebola Patient Dies in Nebraska at Bloomberg
12:29PM  Story Stocks from Briefing.com Briefing.com
12:23PM  Docs Were Concerned Valeant Would Acquire Allergan: Survey at The Wall Street Journal
12:12PM  AGN INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Allergan Inc. in Connection With the Fairness of the Sale of the Company to Actavis plc Business Wire
12:10PM  Actavis to spend $66B on Allergan AP
11:55AM  Done deal: Actavis buying Allergan for $66 billion at CNBC
11:54AM  Actavis Agrees to Buy Allergan for $66B at Bloomberg
Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sherman Scott DExecutive Vice President, HRApr 22Option Exercise75.5810,000755,80018,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 22Sale163.0010,0001,630,0008,223Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Option Exercise73.044,500328,68012,723Apr 23 07:25 PM
Sherman Scott DExecutive Vice President, HRApr 21Sale139.854,500629,3258,223Apr 23 07:25 PM
LAVIGNE LOUIS J JRDirectorFeb 21Sale125.795,400679,2440Feb 24 07:59 PM
INGRAM DOUGLAS SPresidentFeb 21Sale125.701961,044Feb 25 05:49 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Option Exercise58.5523,0001,346,65029,401Feb 21 04:56 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Option Exercise40.1638,9001,562,22455,491Feb 21 04:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 19Sale126.6623,0002,913,1116,401Feb 21 04:56 PM
HUDSON DAWN EDirectorFeb 19Sale126.354,200530,68311,600Feb 21 05:14 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 19Sale126.3938,9004,916,49316,591Feb 21 04:59 PM
Sherman Scott DExecutive Vice President, HRFeb 18Option Exercise75.585,000377,90013,220Feb 19 02:44 PM
Sherman Scott DExecutive Vice President, HRFeb 18Sale125.745,000628,7008,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Option Exercise55.9884,0004,701,90085,058Feb 19 02:41 PM
Sherman Scott DExecutive Vice President, HRFeb 14Sale124.761708,220Feb 19 02:44 PM
INGRAM DOUGLAS SPresidentFeb 14Sale124.4084,00010,449,4321,058Feb 19 02:41 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Option Exercise36.15252,0009,109,800417,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Option Exercise65.9223,8751,573,76930,754Feb 13 05:54 PM
PYOTT DAVID E IChairman of the Board and CEOFeb 12Sale123.12252,00031,025,560165,000Feb 13 05:49 PM
BARLOW JAMES FSR. VP, Corp. Controller (PAO)Feb 12Sale123.5223,8752,949,0416,879Feb 13 05:54 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Option Exercise55.9817,000951,57523,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Option Exercise55.2054,6003,014,01924,123Feb 13 05:59 PM
Diradoorian Raymond HEVPGlobal Technical OperationsFeb 11Sale121.8217,0002,070,9576,401Feb 13 05:56 PM
LAVIGNE LOUIS J JRDirectorFeb 11Sale122.3954,6006,682,69612,723Feb 13 05:59 PM
Sherman Scott DExecutive Vice President, HRFeb 10Option Exercise75.585,000377,90013,325Feb 11 08:41 PM
Sherman Scott DExecutive Vice President, HRFeb 10Sale120.005,000600,0008,325Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Option Exercise64.47105,5006,801,585122,371Feb 11 08:37 PM
Sherman Scott DExecutive Vice President, HRFeb 07Option Exercise73.044,500328,68012,825Feb 11 08:41 PM
EDWARDS JEFFREY LEVP, Fin & Bus. Dev., CFOFeb 07Sale117.74105,50012,421,04316,871Feb 11 08:37 PM
Sherman Scott DExecutive Vice President, HRFeb 07Sale118.554,500533,4848,325Feb 11 08:41 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 14Option Exercise55.9842,0002,350,95059,327Jan 15 06:24 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 14Sale117.8042,0004,947,60017,327Jan 15 06:24 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 08Option Exercise55.9842,0002,350,95059,327Jan 10 06:37 PM
Whitcup Scott MExecutive VP, R&D, CSOJan 08Sale113.8042,0004,779,60017,327Jan 10 06:37 PM
Gangolli Julian SCVP & Pres, North AmericaDec 27Option Exercise53.7152,5002,819,77545,547Dec 30 05:18 PM
Gangolli Julian SCVP & Pres, North AmericaDec 27Sale110.0552,5005,777,5508,047Dec 30 05:18 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Option Exercise36.1533,0001,192,95033,827Dec 20 07:41 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Option Exercise0.0033,000033,827Jan 06 06:27 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Sale108.8033,0003,590,40017,327Jan 06 06:27 PM
Whitcup Scott MExecutive VP, R&D, CSODec 20Sale108.8033,0003,590,40017,327Dec 20 07:41 PM
HUDSON DAWN EDirectorNov 27Sale97.463,000292,38215,800Dec 02 04:52 PM